Introduction
Many hormones and neurotransmitters exert some of their effects by raising the Ca2" concentration in the cytosol of their target cells. Examples of such agonists are epinephrine, norepinephrine, acetylcholine, vasopressin, angiotensin II, cholecystokinin, histamine, serotonin, substance P, some of the hypothalamic releasing hormones, platelet activating factors, and chemotactic peptides. These agonists exert their effects on cell Ca2" by interacting with surface receptors that are distinct from those that mediate changes in cyclic AMP (cAMP) e.g., a1-adrenergic, Ml muscarinic cholinergic, Vl vasopressin, and H1 histamine receptors. Typical Ca2"-mediated responses are the contraction of smooth muscle in blood vessels and other tissues, the secretion of salivary, lacrimal, sweat, and pancreatic glands, the release of certain pituitary hormones, aldosterone and insulin, and secretory or other responses in platelets, neutrophils, mast cells, and lymphocytes. In addition, many Ca2"-mediated agonists act as neurotransmitters.
Changes in cell calcium induced by calciummediated agonists Fig . I shows the mechanisms involved in the regulation of Ca2" in mammalian cells. Ca2" enters cells through selective plasma membrane channels that are either membrane potentialdependent or -independent (1) . In addition, Ca2+ may enter through the Na' channel or by a Na+/Ca2+ exchanger (1) .
To prevent the pathological accumulation of Ca2 , cells possess a plasma membrane Ca2' ATPase pump that maintains cytosolic Ca2+ at a resting level of 0.1-0.2 ,M (1). The Na+/ Ca2" exchanger also acts mainly to extrude Ca2+ (1) . The Ca2+ pump acts as a low capacity system with high affinity for Ca2+, whereas the reverse is true for the exchanger.
In addition to plasma membrane systems, intracellular mechanisms control cytosolic Ca2+ (Fig. 1 ). These mainly involve the endoplasmic (sarcoplasmic) reticulum and mitochondria, which take up or release Ca2+ (2) . Certain membranes and other cellular constituents also bind and buffer cytosolic Ca2". Ca2+ uptake by endoplasmic reticulum occurs by an ATPase, whereas that by mitocheNndria involves a specific carrier and is driven by the proton m7 -force (2 (2, 4) . Endoplasmic reticulum is the major source of mobilized Ca2+ (5), but it possibly also comes from mitochondria or the plasma membrane (2, 4) . The mechanism of release of internal Ca2t (Fig. 2) is discussed in detail below.
The internal stores of Ca2t in most cells are limited.
Therefore, a hormone effect based solely on intracellular Ca2" release would be of short duration, since Ca2" released into the cytosol is rapidly extruded by the plasma membrane pump (4) . Ca2"-mediated agonists, therefore, also affect the flux of Ca2" across the plasma membrane and prolong the increase in cytosolic Ca2" and resultant physiological responses (1, 4 Calmodulin-dependent and -independent processes involved in the actions ofcalcium-mediated agonists
As illustrated in Fig. 2 , many responses to Ca2t-mediated agonists involve binding of Ca2t to calmodulin and subsequent interaction of the Ca2t1calmodulin complex with specific or multifunctional calmodulin-dependent protein kinases or other enzymes and proteins (6) . In addition, the diacylglycerol released during agonist-induced breakdown of plasma membrane phosphoinositides (Fig. 2) produces responses through activation of protein kinase C, a Ca2t-phospholipid-dependent protein kinase (7). Smooth muscle contraction is a major response to norepinephrine, acetylcholine, and many other Ca2"-mediated agonists. The mechanism involves a rise in cytosolic Ca2 , leading to an increase in Ca2t bound to calmodulin, which increases the activity of myosin light chain kinase and leads to phosphorylation of the 22,000-mol-wt light chains of myosin (6) . Since smooth muscle myosin must be phosphorylated to interact with actin, the mechanism increases myosin ATPase activity and cross-bridge cycling, i.e., contraction. Protein kinase C can also phosphorylate myosin light chains (8) and may be involved in contraction in some smooth muscles (9) .
Ca?' (P'2mM) Figure 1 . General mechanisms of regulation of cytosolic Ca2" in cells.
ER, endoplasmic reticulum; Mito, mitochondria; PDC, potentialdependent channels; ROC, receptor-operated channels.
troponin, allowing myosin to interact with actin, thus leading to contraction of skeletal and cardiac striated muscles (10).
Other direct-acting intracellular receptors of calcium are among a class of proteins that includes gelsolin, villin, and fragmin. These proteins, in the presence of submicromolar calcium nucleate actin filament assembly, sever actin filaments along their lengths and block actin monomer exchange at their fastgrowing ends (11). These effects may be important for rapid cell shape changes and for secretion by exocytosis. Secretory responses in salivary, lacrimal and sweat glands, and in exocrine pancreas and gastric parietal cells are observed with certain Ca2"-mediated agonists. In salivary and lacrimal glands, the rise in cytosolic Ca2" increases the K+ permeability of the plasma membrane (12) , and there is evidence that the resulting outflow of K+ leads to the secretion of H20, Na+, and Cl-. Protein kinase C appears not to be involved in the increase in K+ permeability, although it may play a role in amylase secretion (13) .
The stimulation of aldosterone secretion by angiotensin II (14, 15) , of prolactin and thyroid-stimulating hormone by thyrotropin-releasing hormone (16) (17) (18) (19) , and of insulin by (19) . Two of these phosphorylations are attributable to Ca2", whereas the others apparently involve protein kinase C (19) . It has been speculated that phosphorylation of several islet proteins, including those associated with microtubules, microfilaments, and secretory granules, by Ca2+-calmodulin-dependent protein kinase and/or protein kinase C underlies glucose-induced insulin secretion (21) (22) (23) . Platelet-activating agents cause platelet aggregation and secretion through mechanisms involving both Ca2+-calmodulindependent protein kinase(s) and protein kinase C (5, 7, 24) . The initial shape change appears to involve phosphorylation of myosin light chains (25) .
Ca2+-mediated agonists cause a rapid breakdown of glycogen in liver due to activation of glycogen phosphorylase and inactivation of glycogen synthase (4) . Phosphorylase activation is due to Ca2" stimulation of phosphorylase kinase, which contains calmodulin as a subunit (4) . Inactivation of glycogen synthase could involve phosphorylase kinase, protein kinase C, or a multifunctional Ca2+-calmodulin-dependent protein kinase (4, 26) . The latter two kinases are probably responsible for the other effects of Ca2+-mediated agonists on liver.
Ca2+-mediated neurotransmitters increase the phosphorylation of specific proteins that are either located throughout the nervous system or limited to one or a few neuron types (27, 28) . Many of these proteins are substrates of Ca2+-calmodulin-dependent protein kinases and/or protein kinase C (27) (28) (29) and are phosphorylated during electrical or drug stimulation (27, 28) . For example, the calmodulin-dependent kinase phosphorylates synapsin 1, which is associated with synaptic vesicles in nerve terminals and controls neurotransmitter release, tyrosine and tryptophan hydroxylases, which control dopamine, norepinephrine or serotonin synthesis, and microtubule and associated proteins (27) (28) (29) . Protein kinase C also phosphorylates many neuronal proteins, including an 87,000-mol-wt protein present in all neurons, and the nicotinic acetylcholine receptor (27) (28) (29) .
Role ofphosphoinositide breakdown in the mechanisms of action of calcium-mediated agonists There is much current excitement concerning the hypothesis that Ca2"-mediated agonists act by stimulating the breakdown of phosphoinositides in the plasma membrane (5, 30) . The hypothesis arose from the pioneering work of Michell and others (31) and is depicted in Fig. 2 PIP2 is a very minor phospholipid formed in the plasma membrane by the sequential phosphorylation of phosphatidylinositol (PI) and phosphatidylinositol 4-phosphate (PIP) by specific kinases (Fig. 3) (5, 30) . It has also been reported that certain tyrosine kinases encoded by viral oncogenes (pp60' and p681) (5, 30) , the insulin receptor tyrosine kinase (32) , and cAMP-dependent protein kinase (33) phosphorylate PI or PIP in vitro. However, the purity of the kinases used in these experiments may be questioned, and at present, the evidence that they control PI phosphorylation in intact cells is equivocal (e.g., 34). The effects of other oncogene products and growth factors on phosphoinositide metabolism are described below.
PIP2 and PIP can be reconverted to PI by the action of phosphomonoesterases (Fig. 3) . In platelets and some other cells, another major pathway of phosphoinositide metabolism is hydrolysis by phospholipase A2 to yield arachidonic acid, which is then converted to a variety of bioactive eicosanoids (7, 30).
As is true for all intracellular messengers, IP3 and DAG turn over rapidly. As shown in Fig. 3, IP3 is sequentially degraded by phosphatases (5) to myoinositol 1,4-bisphosphate, myoinositol 1-phosphate, and myoinositol. None of these is effective in mobilizing intracellular Ca2' (5) . DAG is converted to phosphatidic acid by diacylglycerol kinase in the plasma membrane (Fig. 3) (7, 30) . It can also be hydrolysed by diacylglycerol and monoacylglycerol lipases (7, 30), but these enzymes are mainly located in sites other than the plasma membrane. Phosphatidate formed from DAG is transferred to the endoplasmic reticulum and used for the synthesis of phospholipids and triacylglycerol (Fig. 3) (5, 30) .
In all of many tissues examined, the first event detected after receptor occupancy by Ca2--mediated agonists is the breakdown of PIP2 and formation of IP3. This occurs sufficiently rapidly to account for the increase in cytosolic Ca2+ (5, 30, 35) . Concentrations of IP3 (20-300 nM), which resemble those PP. P14,5P2, PIP2; RI, surface receptor, R2, putative ER (endoplasmic reticulum) receptor for IP3. calculated to occur in the cytosol, also instantly release intracellular Ca2+ in permeabilized cells of several types (5, 30) (Thiyagarajah, P., R. Charest, J. H. Exton, and P. F. Blackmore, manuscript submitted for publication) and mobilize Ca2+ from isolated microsomes (5) and mitochondria (Thiyagarajah, P., R. Charest, J. H. Exton, and P. F. Blackmore, manuscript submitted for publication). These observations strongly support the postulated role of IP3 as the messenger for intracellular Ca2+ mobilization.
Due to the presence of spare receptors for most Ca2+_ mediated agonists, occupancy of only a fraction of total receptors with the generation of submaximal concentrations of IP3 is sufficient to elicit maximal physiological responses in most situations (Lynch, C. J., P. F. Blackmore, R. Charest, and J. H. Exton, manuscript submitted for publication). This signal amplification resembles that observed for many cAMPmediated agonists and gives rise to a large separation in the dose-response curves for IP3 formation and responses in certain cells (35) .
Little is known concerning the coupling of receptors to PIP2 breakdown, but there is indirect evidence that a guanine nucleotide binding regulatory protein is involved, as is the case for the receptors coupled to adenylate cyclase. For (52, 53) . PMA inhibits binding to the insulin, EGF, and a,-adrenergic receptors (54) (55) (56) , suggesting that protein kinase C may regulate these and other receptors.
In many cell types, the Ca2+ pathway of agonist action interacts synergistically with the DAG pathway (7, 30). This synergism is seen in the aggregatory and secretory responses of platelets (7, 24, 30), exocytosis in neutrophils (5, 7, 57), histamine release from mast cells (7), aldosterone and insulin secretion (5, 15, 58) , contraction in certain smooth muscles (5, 9, 59) , and mitosis in lymphocytes (7). The synergism may be due to the combined effects of Ca2" and DAG on protein kinase C or to more distal events. For example, the response may depend on the phosphorylation of one or more proteins by both calmodulin-and phospholipid-dependent protein kinases or on the interaction of several proteins phosphorylated by either kinase.
In summary, there has been much recent progress in understanding the molecular mechanisms by which Ca2+-mediated agonists exert their widespread physiological effects. Of particular interest is the fact that two intracellular messengers are involved, namely, Ca2' and diacylglycerol. These may act separately to produce physiological responses, but often they interact synergistically. Despite the rapid advance in knowledge in this area, many points remain to be clarified. These include the coupling between the receptors and PIP2 breakdown, the mechanism by which IP3 releases intracellular Ca2 , the changes in plasma membrane Ca2' fluxes and how they are caused, and the enzymes and other proteins involved in all the responses to the agonists.
